权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

1 型糖尿病微血管功能障碍的治疗策略

基本信息

批准号：
10590208
负责人：
Kaitlin M Love
金额：
$ 19.2万
依托单位：
UNIVERSITY OF VIRGINIA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-01-01 至 2027-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10590208
关键词：
Address Adjuvant Therapy Adult Agonist Antioxidants Arteries Attenuated Award Biometry Blood Vessels Cardiovascular Diseases Cell physiology Cells Cellular biology Cessation of life Chronic Clinical Research Clinical Trials Data Data Analyses Disease Outcome Endothelial Cells Endothelium Ensure Exercise Exercise Tolerance Exhibits Future GLP-I receptor Glucose Goals Harvest Health Heart failure Human Hyperglycemia Impairment Individual Institution Insulin Insulin Resistance Insulin-Dependent Diabetes Mellitus Interval training Investigation Knowledge Link Measures Mediating Mentors Mentorship Methodology Microvascular Dysfunction Modality Muscle Muscle function NOS3 gene Nitric Oxide Non-Insulin-Dependent Diabetes Mellitus Obesity Outcome Oxidative Stress Oxidative Stress Induction Oxygen Participant Pathway interactions Perfusion Persons Phosphorylation Physical activity Physiological Pilot Projects Placebos Plasma Play Population Production Public Health Randomized Reactive Oxygen Species Research Resources Role Signal Transduction Site Skeletal Muscle Stains Stimulus Techniques Testing Therapeutic Tissues Training United States National Institutes of Health VO2max Vascular Endothelium Vasodilation Work Youth cardiorespiratory fitness cardiovascular disorder risk cardiovascular effects career contrast enhanced data management endothelial dysfunction exercise adherence exercise training fitness glucagon-like peptide 1 glucose uptake improved improved outcome in vivo innovation insight post intervention prevent response ultrasound uptake vascular endothelial dysfunction

项目摘要

PROJECT SUMMARY/ABSTRACT Cardiovascular disease (CVD) is markedly elevated in type 1 diabetes (T1D), and two prevalent conditions in T1D, insulin resistance and endothelial dysfunction, precede and predict CVD. In health, insulin action at the endothelial cell dilates blood vessels, which promotes glucose and insulin delivery to muscle for glucose uptake. We recently showed, in adults with uncomplicated T1D, insulin commonly fails to enhance muscle microvascular perfusion, indicating microvascular insulin resistance, and even youth with T1D have apparent microvascular endothelial dysfunction. This is significant since the microvasculature is critical for muscle health as the direct supplier and exchange site of substrates. Possibly due to impaired muscle health from microvascular dysfunction, the T1D population has diminished cardiorespiratory fitness, even when matched for activity. Mechanisms of microvascular dysfunction in T1D remain ill-defined, but oxidative stress (OS) contributes to endothelial dysfunction at large arteries and likely the microvasculature as well. OS is clearly amplified in T1D. Adjuvant treatments to improve endothelial function and fitness are critically needed in T1D, and such therapies have potential to prevent CVD in future studies. Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RA) improve: microvascular function in insulin resistant states, OS outside of glucose effects, cardiorespiratory fitness, and CVD outcomes in type 2 diabetes (T2D). Exercise attenuates large artery endothelial function and OS in T1D, and it improves microvascular endothelial function in T2D. Whether GLP- 1RA or exercise training improve muscle microvascular endothelial function in T1D is unknown. This project will test the hypothesis that, in adults with T1D, GLP-1RA and exercise training each enhance insulin-stimulated muscle microvascular perfusion via attenuating endothelial OS and improving endothelial cell function. Using cutting-edge contrast enhanced ultrasound before and after randomization to 14-wks of: 1) GLP-1RA, 2) exercise training, or 3) placebo, this study will assess whether GLP-1R agonism (Aim 1) or exercise training (Aim 2) improves insulin-mediated microvascular perfusion and muscle function in adults with T1D. Finally, harvesting and analyzing endothelial cells using an innovative technique will assess whether these therapies attenuate endothelial cell OS and improve endothelial function in vivo (Aim 3). Significantly, completion of the proposed studies will increase mechanistic knowledge of microvascular endothelial dysfunction in T1D and ascertain if larger studies examining GLP-1RA and exercise alone/combined are merited and feasible. The proposed research and training will support the candidate’s long-term goal to conduct larger clinical studies in T1D aiming to reverse endothelial dysfunction/prevent CVD. Preparing for that end, goals for this award are training in T1D- focused clinical trial work, human endothelial cell harvesting + cell biology, and biostatistics + data management. A robust mentorship team, with complementary expertise, and abundant institutional resources will ensure successful project completion and facilitate the promising candidate’s future independent research career.